SPECIAL NOTICE
A -- RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
- Notice Date
- 9/10/2024 4:04:27 AM
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
- ZIP Code
- 20515
- Solicitation Number
- RRPV-24-02-OralVx
- Response Due
- 10/18/2024 10:00:00 AM
- Archive Date
- 11/02/2024
- Point of Contact
- Rebecca Harmon
- E-Mail Address
-
rebecca.harmon@ati.org
(rebecca.harmon@ati.org)
- Description
- This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) titled, ""NextGen Oral Formulation Vaccines for COVID-19"".� The purpose of this effort is to�advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, improve our understanding of their potential, and to provide better COVID-19 solutions and bolster preparedness and response against future health security threats.�The full RPP and information on joining the consortium can be accessed through the RRPV website at www.rrpv.org.�
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/f18489c2eaa7407e83be17d684ab96e5/view)
- Place of Performance
- Address: DC, USA
- Country: USA
- Country: USA
- Record
- SN07204786-F 20240912/240910230115 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |